Oncotelic's Sapu003 Accepted for Presentation at 2025 San Antonio Breast Cancer Symposium

The acceptance of Oncotelic Therapeutics, Inc.'s investigational intravenous Deciparticle(TM) everolimus, known as Sapu003, for presentation at the 2025 San Antonio Breast Cancer Symposium represents a significant validation of its potential clinical relevance. This novel formulation, developed by Sapu Nano, a joint venture between Oncotelic and Dragon Oversea, is specifically designed for HR⁺/HER2⁻ metastatic breast cancer, renal cell carcinoma, and neuroendocrine tumors. The symposium, scheduled for December 9-12, 2025, serves as a premier international platform for presenting cutting-edge breast cancer research, making this acceptance an important milestone in the drug's development pathway.

The significance of this development lies in Sapu003's potential to address critical limitations of current cancer treatments. The Deciparticle(TM) formulation of everolimus aims to improve bioavailability, reduce toxicity, and enhance tumor penetration compared to existing therapies. This represents a meaningful advancement for patients with HR⁺/HER2⁻ metastatic breast cancer, a subtype where treatment optimization remains crucial for improving outcomes and quality of life. As breast cancer remains one of the most prevalent cancers worldwide, advancements in treatment formulations that offer improved efficacy with reduced side effects could significantly impact patient care and treatment outcomes in the coming years.

Oncotelic Therapeutics operates as a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products, with a mission to address high-unmet-need cancers and rare pediatric indications. The company maintains a robust intellectual property portfolio through its CEO, Dr. Vuong Trieu, who has filed more than 150 patent applications and holds 39 issued U.S. patents. Additional information about the company is available in their newsroom at https://ibn.fm/OTLC.

Beyond its direct development programs, Oncotelic maintains strategic partnerships through joint ventures, including its 45% ownership in GMP Bio, which advances complementary drug candidates in oncology and rare disease therapeutics. This collaborative approach strengthens the company's position in developing transformative cancer therapies through its PDAOAI platform and expertise in nanomedicines. The full press release detailing this announcement can be accessed at https://ibn.fm/wB4Hl.

The presentation of Sapu003 data at the 2025 symposium marks an important step forward in the evaluation of this innovative treatment approach. The Deciparticle(TM) technology represents a novel approach to drug delivery that could potentially overcome some of the most persistent challenges in cancer therapy, particularly for difficult-to-treat cancers like HR⁺/HER2⁻ metastatic breast cancer. This acceptance at a prestigious scientific meeting indicates growing recognition of the formulation's scientific merit and clinical potential within the oncology research community.